|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J,
Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin.
58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bast RC Jr, Hennessy B and Mills GB: The
biology of ovarian cancer: New opportunities for translation. Nat
Rev Cancer. 9:415–428. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Alvero AB, Chen R, Fu HH, Montagna M,
Schwartz PE, Rutherford T, Silasi DA, Steffensen KD, Waldstrom M,
Visintin I, et al: Molecular phenotyping of human ovarian cancer
stem cells unravels the mechanisms for repair and chemoresistance.
Cell Cycle. 8:158–166. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fotopoulou C, Richter R, Braicu IE,
Schmidt SC, Neuhaus P, Lichtenegger W and Sehouli J: Clinical
outcome of tertiary surgical cytoreduction in patients with
recurrent epithelial ovarian cancer. Ann Surg Oncol. 18:49–57.
2011. View Article : Google Scholar
|
|
5
|
Husseinzadeh N: Status of tumor markers in
epithelial ovarian cancer has there been any progress? A review
Gynecol Oncol. 120:152–157. 2011. View Article : Google Scholar
|
|
6
|
Hiss D: Optimizing molecular-targeted
therapies in ovarian cancer: The renewed surge of interest in
ovarian cancer biomarkers and cell signaling pathways. J Oncol.
2012:7379812012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kaye SB, Colombo N, Monk BJ, Tjulandin S,
Kong B, Roy M, Chan S, Filipczyk-Cisarz E, Hagberg H, Vergote I, et
al: Trabectedin plus pegylated liposomal doxorubicin in relapsed
ovarian cancer delays third-line chemotherapy and prolongs the
platinum-free interval. Ann Oncol. 22:49–58. 2011. View Article : Google Scholar
|
|
8
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang S, Balch C, Chan MW, Lai HC, Matei
D, Schilder JM, Yan PS, Huang TH and Nephew KP: Identification and
characterization of ovarian cancer-initiating cells from primary
human tumors. Cancer Res. 68:4311–4320. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lipovich L, Johnson R and Lin CY: MacroRNA
underdogs in a microRNA world: Evolutionary, regulatory, and
biomedical significance of mammalian long non-protein-coding RNA.
Biochim Biophys Acta. 1799:597–615. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang H, Huo X, Yang XR, He J, Cheng L,
Wang N, Deng X, Jin H, Wang N, Wang C, et al: STAT3-mediated
upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer
metastasis by regulating SOX4. Mol Cancer. 16:1362017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cui Z, Ren S, Lu J, Wang F, Xu W, Sun Y,
Wei M, Chen J, Gao X, Xu C, et al: The prostate cancer-up-regulated
long noncoding RNA PlncRNA-1 modulates apoptosis and proliferation
through reciprocal regulation of androgen receptor. Urol Oncol.
31:1117–1123. 2013. View Article : Google Scholar
|
|
13
|
Wu DD, Chen X, Sun KX, Wang LL, Chen S and
Zhao Y: Role of the lncRNA ABHD11-AS1 in the tumorigenesis and
progression of epithelial ovarian cancer through targeted
regulation of RhoC. Mol Cancer. 16:1382017. View Article : Google Scholar :
|
|
14
|
Parasramka M, Yan IK, Wang X, Nguyen P,
Matsuda A, Maji S, Foye C, Asmann Y and Patel T: BAP1 dependent
expression of long non-coding RNA NEAT-1 contributes to sensitivity
to gemcitabine in cholangiocarcinoma. Mol Cancer. 16:222017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yap TA, Carden CP and Kaye SB: Beyond
chemotherapy: Targeted therapies in ovarian cancer. Nat Rev Cancer.
9:167–181. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rowan K: Intraperitoneal therapy for
ovarian cancer: Why has it not become standard? J Natl Cancer Inst.
101:775–777. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Benedet JL, Bender H, Jones H III, Ngan HY
and Pecorelli S: FIGO staging classifications and clinical practice
guidelines in the management of gynecologic cancers. Int J Gynaecol
Obstet. 70:209–262. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lisowska KM, Olbryt M, Dudaladava V,
Pamuła-Piłat J, Kujawa K, Grzybowska E, Jarząb M, Student S,
Rzepecka IK, Jarząb B, et al: Gene expression analysis in ovarian
cancer - faults and hints from DNA microarray study. Front Oncol.
4:62014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Koti M, Gooding RJ, Nuin P, Haslehurst A,
Crane C, Weberpals J, Childs T, Bryson P, Dharsee M, Evans K, et
al: Identification of the IGF1/PI3K/NF κB/ERK gene signalling
networks associated with chemotherapy resistance and treatment
response in high-grade serous epithelial ovarian cancer. BMC
Cancer. 13:5492013. View Article : Google Scholar
|
|
20
|
Li M, Balch C, Montgomery JS, Jeong M,
Chung JH, Yan P, Huang TH, Kim S and Nephew KP: Integrated analysis
of DNA methylation and gene expression reveals specific signaling
pathways associated with platinum resistance in ovarian cancer. BMC
Med Genomics. 2:342009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tothill RW, Tinker AV, George J, Brown R,
Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro
B, et al: Novel molecular subtypes of serous and endometrioid
ovarian cancer linked to clinical outcome. Clin Cancer Res.
14:5198–5208. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sugio A, Yang B, Zhu T and White FF: Two
type III effector genes of Xanthomonas oryzae pv. oryzae control
the induction of the host genes OsTFIIAgamma1 and OsTFX1 during
bacterial blight of rice. Proc Natl Acad Sci USA. 104:10720–10725.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Miller JA, Cai C, Langfelder P, Geschwind
DH, Kurian SM, Salomon DR and Horvath S: Strategies for aggregating
gene expression data: The collapseRows R function. BMC
Bioinformatics. 12:3222011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li J, Han L, Roebuck P, Diao L, Liu L,
Yuan Y, Weinstein JN and Liang H: TANRIC: An interactive open
platform to explore the function of lncRNAs in cancer. Cancer Res.
75:3728–3737. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBio-Portal. Sci Signal. 6:pl12013. View Article : Google Scholar
|
|
26
|
Volders PJ, Helsens K, Wang X, Menten B,
Martens L, Gevaert K, Vandesompele J and Mestdagh P: LNCipedia: A
database for annotated human lncRNA transcript sequences and
structures. Nucleic Acids Res. 41:D246–D251. 2013. View Article : Google Scholar :
|
|
27
|
Du Z, Fei T, Verhaak RG, Su Z, Zhang Y,
Brown M, Chen Y and Liu XS: Integrative genomic analyses reveal
clinically relevant long noncoding RNAs in human cancer. Nat Struct
Mol Biol. 20:908–913. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Harrow J, Frankish A, Gonzalez JM,
Tapanari E, Diekhans M, Kokocinski F, Aken BL, Barrell D, Zadissa
A, Searle S, et al: GENCODE: The reference human genome annotation
for The ENCODE Project. Genome Res. 22:1760–1774. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu C, Bai B, Skogerbø G, Cai L, Deng W,
Zhang Y, Bu D, Zhao Y and Chen R: NONCODE: An integrated knowledge
database of non-coding RNAs. Nucleic Acids Res. 33:D112–D115. 2005.
View Article : Google Scholar :
|
|
30
|
Wilkerson MD and Hayes DN:
ConsensusClusterPlus: A class discovery tool with confidence
assessments and item tracking. Bioinformatics. 26:1572–1573. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Smyth GK: Linear models and empirical
bayes methods for assessing differential expression in microarray
experiments. Stat Appl Genet Mol Biol. 3:1–25. 2004. View Article : Google Scholar
|
|
32
|
Hakulinen T and Abeywickrama KH: A
computer program package for relative survival analysis. Comput
Programs Biomed. 19:197–207. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Verhaak RG, Tamayo P, Yang JY, Hubbard D,
Zhang H, Creighton CJ, Fereday S, Lawrence M, Carter SL, Mermel CH,
et al Cancer Genome Atlas Research Network: Prognostically relevant
gene signatures of high-grade serous ovarian carcinoma. J Clin
Invest. 123:517–525. 2013.
|
|
34
|
Duda RO, Hart PE and Stork DG: Pattern
Classification. China Machine Press; 2012
|
|
35
|
Sing T, Beerenwinkel N and Lengauer T:
Learning mixtures of localized rules by maximizing the area under
the ROC curve. In: ROCAI-2004. Hernández-Orallo José: 1st
International Workshop on ROC Analysis in Artificial Intelligence;
Valencia. pp. 89–96. 2004
|
|
36
|
Zhou M, Sun Y, Sun Y, Xu W, Zhang Z, Zhao
H, Zhong Z and Sun J: Comprehensive analysis of lncRNA expression
profiles reveals a novel lncRNA signature to discriminate
nonequivalent outcomes in patients with ovarian cancer. Oncotarget.
7:32433–32448. 2016.PubMed/NCBI
|
|
37
|
Liu R, Zeng Y, Zhou CF, Wang Y, Li X, Liu
ZQ, Chen XP, Zhang W and Zhou HH: Long noncoding RNA expression
signature to predict platinum-based chemotherapeutic sensitivity of
ovarian cancer patients. Sci Rep. 7:182017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Network TCGA; Cancer Genome Atlas Research
Network: Integrated genomic analyses of ovarian carcinoma. Nature.
474:609–615. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tomczak K, Czerwińska P and Wiznerowicz M:
The Cancer Genome Atlas (TCGA): An immeasurable source of
knowledge. Contemp Oncol (Pozn). 19:A68–A77. 2015.
|
|
40
|
Barretina J, Caponigro G, Stransky N,
Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV,
Sonkin D, et al: The Cancer Cell Line Encyclopedia enables
predictive modelling of anticancer drug sensitivity. Nature.
483:603–607. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Miow QH, Tan TZ, Ye J, Lau JA, Yokomizo T,
Thiery JP and Mori S: Epithelial-mesenchymal status renders
differential responses to cisplatin in ovarian cancer. Oncogene.
34:1899–1907. 2015. View Article : Google Scholar
|
|
42
|
Thorvaldsdóttir H, Robinson JT and Mesirov
JP: Integrative Genomics Viewer (IGV): High-performance genomics
data visualization and exploration. Brief Bioinform. 14:178–192.
2013. View Article : Google Scholar :
|
|
43
|
Consortium GO: The Gene Ontology (GO)
database and informatics resource. Nucleic Acids Res. 32:D258–D261.
2004. View Article : Google Scholar :
|
|
44
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Brannon AR, Haake SM, Hacker KE, Pruthi
RS, Wallen EM, Nielsen ME and Rathmell WK: Meta-analysis of clear
cell renal cell carcinoma gene expression defines a variant
subgroup and identifies gender influences on tumor biology. Eur
Urol. 61:258–268. 2012. View Article : Google Scholar
|
|
46
|
Watt JP, O'Brien KL, Benin AL, McCoy SI,
Donaldson CM, Reid R, Schuchat A, Zell ER, Hochman M, Santosham M,
et al: Risk factors for invasive pneumococcal disease among Navajo
adults. Am J Epidemiol. 166:1080–1087. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Dhillon KK, Swisher EM and Taniguchi T:
Secondary mutations of BRCA1/2 and drug resistance. Cancer Sci.
102:663–669. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sakai W, Swisher EM, Karlan BY, Agarwal
MK, Higgins J, Friedman C, Villegas E, Jacquemont C, Farrugia DJ,
Couch FJ, et al: Secondary mutations as a mechanism of cisplatin
resistance in BRCA2-mutated cancers. Nature. 451:1116–1120. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhang N, Yang GQ, Shao XM and Wei L: GAS5
modulated autophagy is a mechanism modulating cisplatin sensitivity
in NSCLC cells. Eur Rev Med Pharmacol Sci. 20:2271–2277.
2016.PubMed/NCBI
|
|
50
|
Li J, Huang H, Li Y, Li L, Hou W and You
Z: Decreased expression of long non-coding RNA GAS5 promotes cell
proliferation, migration and invasion, and indicates a poor
prognosis in ovarian cancer. Oncol Rep. 36:3241–3250. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Gao J, Liu M, Zou Y, Mao M, Shen T, Zhang
C, Song S, Sun M, Zhang S, Wang B, et al: Long non-coding RNA
growth arrest-specific transcript 5 is involved in ovarian cancer
cell apoptosis through the mitochondria-mediated apoptosis pathway.
Oncol Rep. 34:3212–3221. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Nagini S: Breast Cancer: Current molecular
therapeutic targets and new players. Anticancer Agents Med Chem.
17:152–163. 2017. View Article : Google Scholar
|
|
53
|
Cray C, Zaias J and Altman NH: Acute phase
response in animals: A review. Comp Med. 59:517–526.
2009.PubMed/NCBI
|
|
54
|
Clendenen TV, Lundin E,
Zeleniuch-Jacquotte A, Koenig KL, Berrino F, Lukanova A, Lokshin
AE, Idahl A, Ohlson N, Hallmans G, et al: Circulating inflammation
markers and risk of epithelial ovarian cancer. Cancer Epidemiol
Biomarkers Prev. 20:799–810. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Kulbe H, Thompson R, Wilson JL, Robinson
S, Hagemann T, Fatah R, Gould D, Ayhan A and Balkwill F: The
inflammatory cytokine tumor necrosis factor-alpha generates an
autocrine tumor-promoting network in epithelial ovarian cancer
cells. Cancer Res. 67:585–592. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Bollrath J and Greten FR: IKK/NF-kappaB
and STAT3 pathways: Central signalling hubs in
inflammation-mediated tumour promotion and metastasis. EMBO Rep.
10:1314–1319. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Duan Z, Foster R, Bell DA, Mahoney J,
Wolak K, Vaidya A, Hampel C, Lee H and Seiden MV: Signal
transducers and activators of transcription 3 pathway activation in
drug-resistant ovarian cancer. Clin Cancer Res. 12:5055–5063. 2006.
View Article : Google Scholar : PubMed/NCBI
|
